Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Actuate Therapeutics Inc.
Pfizer
University of California, Davis
Institut Bergonié
M.D. Anderson Cancer Center
Mayo Clinic
University of Salamanca
Washington University School of Medicine
Incyte Corporation
Washington University School of Medicine
Trishula Therapeutics, Inc.
Intensity Therapeutics, Inc.
Zealand University Hospital
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
Checkpoint Therapeutics, Inc.
University of Toronto
The Christie NHS Foundation Trust
National Cancer Institute (NCI)
Zhejiang Provincial People's Hospital
Washington University School of Medicine
Cedars-Sinai Medical Center
Centre Hospitalier Henri Duffaut - Avignon
Celldex Therapeutics
Corvus Pharmaceuticals, Inc.
Eastern Cooperative Oncology Group
ImmVira Pharma Co. Ltd
Blue Note Therapeutics
Università Politecnica delle Marche
Incyte Corporation
University Health Network, Toronto
Hospices Civils de Lyon
Institut Bergonié
Mid and South Essex NHS Foundation Trust
Celgene
Case Comprehensive Cancer Center
Dana-Farber Cancer Institute
University of Wisconsin, Madison
Shenzhen BinDeBio Ltd.
Shanghai Junshi Bioscience Co., Ltd.
University of Chicago
National Institutes of Health Clinical Center (CC)
Amgen
Royal Brompton & Harefield NHS Foundation Trust
Ohio State University Comprehensive Cancer Center
Heidelberg University
Alliance for Clinical Trials in Oncology
AHS Cancer Control Alberta